2015
DOI: 10.1016/j.bbrc.2015.05.064
|View full text |Cite
|
Sign up to set email alerts
|

ER stress-associated CTRC mutants decrease stimulated pancreatic zymogen secretion through SIRT2-mediated microtubule dysregulation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 26 publications
0
6
0
Order By: Relevance
“…In addition, there are a variety of protective mechanisms against premature zymogen activation in vivo through the inhibition or degradation of activated trypsin (Hirota et al, 2006; Binker et al, 2015). These mechanisms include inhibition by pancreatic secretory trypsin inhibitor (PSTI), also known as a serine protease inhibitor Kazal-type 1 (SPINK1) or tumor-associated trypsin inhibitor (TATI) (Hirota et al, 2006), and degradation by chymotrypsin-C (CTRC) (Binker et al, 2015) and the lysosomal hydrolase cathepsin-L (Wartmann et al, 2010).…”
Section: Underlying Mechanisms Of Apmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, there are a variety of protective mechanisms against premature zymogen activation in vivo through the inhibition or degradation of activated trypsin (Hirota et al, 2006; Binker et al, 2015). These mechanisms include inhibition by pancreatic secretory trypsin inhibitor (PSTI), also known as a serine protease inhibitor Kazal-type 1 (SPINK1) or tumor-associated trypsin inhibitor (TATI) (Hirota et al, 2006), and degradation by chymotrypsin-C (CTRC) (Binker et al, 2015) and the lysosomal hydrolase cathepsin-L (Wartmann et al, 2010).…”
Section: Underlying Mechanisms Of Apmentioning
confidence: 99%
“…These mechanisms include inhibition by pancreatic secretory trypsin inhibitor (PSTI), also known as a serine protease inhibitor Kazal-type 1 (SPINK1) or tumor-associated trypsin inhibitor (TATI) (Hirota et al, 2006), and degradation by chymotrypsin-C (CTRC) (Binker et al, 2015) and the lysosomal hydrolase cathepsin-L (Wartmann et al, 2010). Once these protective mechanisms are expended, there is an increased risk of developing AP.…”
Section: Underlying Mechanisms Of Apmentioning
confidence: 99%
“…Enzyme activities were calculated as units per milligram (U/mg) of protein. The content of protein was detected by using the bicinchoninic acid (BCA) method (Binker et al, 2015).…”
Section: Determination Of Cellular Antioxidant Enzymesmentioning
confidence: 99%
“…Pancreatic cells can produce the corresponding ERS response under the stimulation from different secretagogues. The expression of mutant chymotrypsin, which is associated with hereditary pancreatitis, leading to the accumulation of a large amount of misfolded CTRC in the ER and further deterioration due to ERS, ultimately regulating trypsin secretion through the ERS pathway . Cholecystokinin can act on pancreatic acinus in AP and regulate PERK to enable eIF2α phosphorylation and inhibit protein synthesis …”
Section: Ers and Apmentioning
confidence: 99%
“…The expression of mutant chymotrypsin, which is associated with hereditary pancreatitis, leading to the accumulation of a large amount of misfolded CTRC in the ER and further deterioration due to ERS, 79 ultimately regulating trypsin secretion through the ERS pathway. 80 Cholecystokinin can act on pancreatic acinus in AP and regulate PERK to enable eIF2α phosphorylation and inhibit protein synthesis. 77 Zymophagy is an endogenous protective mechanism of the pancreas that was newly discovered by in AP in 2011.…”
Section: Trypsinogen and Zymophagymentioning
confidence: 99%